IL10 and asthma: Additionally, oral administration of ScLL reduced IL-4 and IL-5 levels in murine models of acute and chronic inflammation and lead to increased IFN-γ and IL-10 production in asthma inflammatory model, directing a shift from Th2- to Th1-biased immune response [30].